Results 91 to 100 of about 2,262 (198)
Changes in serum LDL, PCSK9 and microRNA?122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir [PDF]
The present study evaluated the changes in lipid profile, and the associations between serum protein convertase subtilisin/kexin 9 (PCSK9),microRNA (miR)122 and low?density lipoprotein variation following treatment of hepatitis C virus (HCV) genotype 1b ...Akahoshi, Hiroshi, Yajima, Hiroyuki, Sasaki, Seina, Nakao, Kazuhiko, Takahashi, Youichi, Ichikawa, Tatsuki, Miuma, Satoshi, Taura, Naota, Uehara, Ryouhei, Honda, Tetsurou, Nakamura, Junpei, Miyaaki, Hisamitsu, Motoyoshi, Yasuhide, Narita, Syouhei, Hino, Naoyuki, Tanaka, Hisaya +15 morecore Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir [PDF]
, 2019 Jun Matsumoto, Su Nwe San, Masachika Fujiyoshi, Ayano Kawauchi, Natsumi Chiba, Ran Tagai, Ryoko Sanbe, Shiho Yanaka, Hiroaki Sakaue, Yoshinori Kato, Hiroyoshi Nakamura, Harumi Yamada, Noritaka Ariyoshi +12 moreopenalex +1 more sourcePre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection
, 2020 Naoki Morishita, Ryotaro Sakamori, Tomomi Yamada, Yugo Kai, Yuki Tahata, Ayako Urabe, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yoshinori Doi, Shinji Tamura, Hideki Hagiwara, Yasuharu Imai, Sadaharu Iio, Tomohide Tatsumi, Tetsuo Takehara +15 moreopenalex +2 more sourcesDiscovery of a
Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis
C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential
for Once-Daily Dosing
, 2016 The
discovery of a back-up to the hepatitis C virus NS3 protease inhibitor
asunaprevir (2) is described. The objective of this work
was the identification of a drug with antiviral properties and toxicology
parameters similar to 2, but with a preclinical ...Paul Falk (1834291), Maria Donoso (3076479), Brian
L. Venables (3076482), Luciano Mueller (1629796), Paul M. Scola (1639726), Sing-Yuen Sit (1834315), Huabin Sun (136356), Donna M. Bilder (1834252), Yong-Hae Han (1834264), Richard Rampulla (1601455), Jacques Friborg (715566), Anthony Cocuzza (1834261), Kathy Mosure (1834165), Barbara Zheng (1834270), Li-Qiang Sun (1834282), Danshi Li (1834276), Qian Zhao (217607), Alicia Ng (1442749), Herbert E. Klei (486974), Paul
C. Levesque (3076500), Ying-Kai Wang (1834240), Mark
I. Cockett (3076488), Dennis Hernandez (1834255), Hua Fang (627909), Jay O. Knipe (1834321), Kevin Kish (1399378), Amy K. Sheaffer (1834249), Eric Mull (3076497), Ny Sin (1834294), Fei Yu (61577), Richard Schartman (2012938), Lucy Sun (448588), Dennis M. Grasela (1834273), Stephen Adams (1780435), Hong Shi (177669), Pirama
Nayagam Arunachalam (3076485), James Loy (2611882), Fiona McPhee (414636), Qi Gao (133189), Steven Levine (127461), Jeffrey Tredup (2213062), Chaoqun Chen (354923), Arvind Mathur (144120), Tatyana Zvyaga (1834306), Yan Chen (4308), William Warner (3076491), Bang-Chi Chen (1565908), Nicholas A. Meanwell (362044), Theerthagiri Palani (3076476), Michael W. Sinz (1834258), Jialong Zhu (1834288), Jie Chen (5892), Ramkumar Rajamani (1442725), Alan Xiangdong Wang (1834303), Sivakumar Ganesan (3076494), Stanley D’Andrea (1834246) +55 morecore +1 more sourceEstudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno
, 2017 © 2017 Objectives To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile.Vargas, C., Soza, Alejandro, A. Soza, Giglio, A., Espinoza, M. A., Soza, A., Espinoza Sepúlveda, Manuel Antonio, C. Vargas, Espinoza, MA, Vargas, C, Soza, A, A. Giglio, Giglio, A, M.A. Espinoza +13 morecore +1 more sourceDurability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study [PDF]
, 2019 Seung Kak Shin, Jin‐Woo Lee, Hannah Ra, Oh Sang Kwon, Jongbeom Shin, Young‐Joo Jin, Sangheun Lee, Ki Jun Han, Young Nam Kim, Tae Hun Kim, Yun Soo Kim, Ju Hyun Kim +11 moreopenalex +1 more sourceFixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
, 2015 IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection.Tse, Edmund, McPhee, Fiona, Hughes, Eric, Poordad, Fred, Sepe, Thomas, Bennett, Michael, Bronowicki, Jean-Pierre, Lee, Samuel S, Sievert, William, Tam, Edward, Levin, James, Conway, Brian, de Lédinghen, Victor, Swenson, E Scott, Jacobson, Ira, Ortiz-Lasanta, Grisell, Yin, Philip D, Boyer, Nathalie, Boparai, Navdeep, Mollison, Lindsay, Bräu, Norbert, Pol, Stanislas, Muir, Andrew J, Reddy, K Rajender, Sulkowski, Mark, Yozviak, Joseph L, DO, FACP, Angus, Peter +26 morecore Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation [PDF]
, 2018 Noboru Harada, Tomoharu Yoshizumi, Toru Ikegami, Shinji Itoh, Norihiro Furusho, Masaki Kato, Shinji Shimoda, Takasuke Fukuhara, Yuji Soejima, Yoshihiko Maehara +9 moreopenalex +1 more sourceThe Daclatasvir/Asunaprevir/Beclabuvir Combination Therapy for Chronic Hepatitis C Patients Experiencing Failure of IFN-Free DAA-Based Therapies
, 2019 Ken Sato, Atsushi Naganuma, Shuichi Saito, Yuichi Yamazaki, Takeshi Kobayashi, Hiroki Tojima, Norio Horiguchi, Satoru Kakizaki, Toshio Uraoka, Hiroshi Ohnishi, Hiroaki Okamoto +10 moreopenalex +1 more source
